Clinical Trials
244 trialsUmbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
Seagen Inc.
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
MAPtivate-6
Pfizer
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Weill Medical College of Cornell University
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Novartis
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Atara Biotherapeutics
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
University of Chicago
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
Seagen Inc.
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
Sanofi
ELiPSE-1
Century Therapeutics, Inc.
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
Regeneron Pharmaceuticals
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Pfizer
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Novartis
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma
Fondazione Italiana Linfomi - ETS
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Roswell Park Cancer Institute
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
University of Washington
ALEXANDER
Autolus Limited
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Biomea Fusion Inc.
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Ipsen
GLEAN-1
Adicet Therapeutics
SWATCH
Antengene Corporation
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
University of Miami
FIRCE-1
CARGO Therapeutics
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
Gamida Cell ltd
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
Celgene
CLL1818
Gruppo Italiano Malattie EMatologiche dell'Adulto
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Nektar Therapeutics
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Seagen Inc.
ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
Case Comprehensive Cancer Center
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Janssen Research & Development, LLC
LOTIS-9
ADC Therapeutics S.A.
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
Oncternal Therapeutics, Inc
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Genmab
A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Hackensack Meridian Health
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
Taiho Oncology, Inc.
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Mustang Bio
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
MingSight Pharmaceuticals, Inc
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
National Institutes of Health Clinical Center (CC)
Imaging Apoptosis for Lymphoma Treatment Response
Washington University School of Medicine